Abbott Laboratories vs Surmodics, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Abbott Laboratories is the larger company by market value: $181.1 B against $487 M for Surmodics, Inc., 372 times as much (market caps of Oct 30, 2026 for Abbott Laboratories and Jan 5, 2024 for Surmodics, Inc.). Surmodics, Inc.'s value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
- Abbott Laboratories had more revenue: $44.3 B in the year to December 2025 against $105 M for Surmodics, Inc. in the year to September 2021.
- Abbott Laboratories earned more: net income of $6.5 B against $4 M for Surmodics, Inc.
- Abbott Laboratories keeps more of each dollar of sales: a net margin of 14.7% against 3.8% for Surmodics, Inc.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Abbott Laboratories ABT · #117 in the world | Surmodics, Inc. SRDX |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Founded | 1888 | 1979 |
| Size | ||
| Market cap | $181.1 B | $487 M* |
| Revenue | $44.3 B | $105 M |
| Net income | $6.5 B▲ best | $4 M |
| Employees | 115,000 | — |
| Valuation | ||
| P/E ratio | 38.5× | — |
| Price to sales | 3.8× | — |
| Price to book | 3.5× | — |
| Free cash flow yield | 4.1% | — |
| Profitability | ||
| Gross margin | 56.4% | — |
| Operating margin | 18.2% | — |
| Net margin | 14.7% | — |
| Return on equity | 13.1% | — |
| Return on invested capital | 11.2% | — |
| Growth | ||
| Revenue growth | 5.7% | — |
| Revenue growth, 3 years a year | 0.5% | — |
| Earnings per share growth | -51.3% | — |
| Financial strength | ||
| Debt to equity | 0.3× | — |
| Cash | ||
| Free cash flow margin | 16.7% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.8% | — |
| Strength scores | ||
| Piotroski F-score | 6 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Jan 2024 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Abbott Laboratories or Surmodics, Inc.?
Abbott Laboratories is the larger company by market value: $181.1 B against $487 M for Surmodics, Inc., 372 times as much (market caps of Oct 30, 2026 for Abbott Laboratories and Jan 5, 2024 for Surmodics, Inc.). Surmodics, Inc.'s value is the last on file, from Jan 5, 2024: no market-data feed is connected for its exchange yet.
Which makes more money, Abbott Laboratories or Surmodics, Inc.?
Abbott Laboratories had more revenue: $44.3 B in the year to December 2025 against $105 M for Surmodics, Inc. in the year to September 2021. Abbott Laboratories earned more: net income of $6.5 B against $4 M for Surmodics, Inc.
Which is more profitable, Abbott Laboratories or Surmodics, Inc.?
Abbott Laboratories keeps more of each dollar of sales: a net margin of 14.7% against 3.8% for Surmodics, Inc.
More about Abbott Laboratories
More about Surmodics, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.